Annexon, Inc. (NASDAQ:ANNX) CFO Jennifer Lew Sells 6,912 Shares

Annexon, Inc. (NASDAQ:ANNX) CFO Jennifer Lew sold 6,912 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $2.92, for a total value of $20,183.04. Following the completion of the sale, the chief financial officer now owns 77,770 shares of the company’s stock, valued at $227,088.40. This trade represents a 8.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jennifer Lew also recently made the following trade(s):

• On Thursday, February 13th, Jennifer Lew sold 1,786 shares of Annexon stock. The stock was sold at an average price of $2.98, for a total value of $5,322.28.

Annexon Trading Down 0.7 %

Shares of ANNX opened at $2.83 on Friday. The firm has a market capitalization of $301.66 million, a price-to-earnings ratio of -2.70 and a beta of 1.07. The firm’s fifty day simple moving average is $4.29 and its 200-day simple moving average is $5.57. Annexon, Inc. has a twelve month low of $2.63 and a twelve month high of $8.40.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets purchased a new position in shares of Annexon in the 4th quarter valued at $59,000. CANADA LIFE ASSURANCE Co purchased a new stake in shares of Annexon during the fourth quarter worth approximately $77,000. E Fund Management Co. Ltd. lifted its stake in shares of Annexon by 36.0% in the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after acquiring an additional 4,086 shares during the period. Forefront Analytics LLC lifted its position in Annexon by 56.8% in the fourth quarter. Forefront Analytics LLC now owns 16,433 shares of the company’s stock valued at $84,000 after purchasing an additional 5,950 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Annexon in the 4th quarter valued at approximately $98,000.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ANNX shares. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Annexon in a report on Tuesday, December 17th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 target price on shares of Annexon in a research report on Friday, November 15th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $15.80.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.